leisure time -WSS

leisure time

author：explore 2025-10-04 11:57:20 - browse：29221

Adam's take main illustration — Molly Ferguson/STAT

This week, a preview of the TUDCA study in ALS and thoughts on how it might impact Amylyx Pharmaceuticals. Also, I chatted with CRISPR Therapeutics CEO Sam Kulkarni about its new investor. Read to the end for some burning questions, random thoughts.

The next ALS data readout — overdue but important

A European academic consortium is expected to announce results soon from a clinical trial investigating the use of a widely available nutritional supplement called tauroursodeoxycholic acid, or TUDCA, in people living with ALS. The outcome of the TUDCA-ALS study could have implications for Amylyx Pharmaceuticals, because TUDCA is one of the two main ingredients in Relyvrio, the company’s approved drug for ALS.

In a recent interview at Amylyx’s Kendall Square headquarters, co-CEOs Justin Klee and Josh Cohen mostly downplayed the suggestion that results from the randomized, placebo-controlled TUDCA study might affect Relyvrio negatively, or even positively.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Senate panel eyes new effort on drug shortages

knowledge

WSS

Colorectal cancer study finds potential in overlooked immune cell

Liquid biopsy for lung cancer is launched by Delfi

Pfizer is about to make a big push in cancer. Will investors listen?

5 ways to address the shortage of health care workers

STAT Madness 2024: Meet the contenders

What to expect at HLTH 2023, the health care industry conference

explore

leisure time

The next ALS data readout — overdue but important

knowledge

Medicare details structure of new drug price negotiation program

Colorectal cancer study finds potential in overlooked immune cell

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Pfizer is about to make a big push in cancer. Will investors listen?

Hepatitis C has a cure — but many Americans still lack access to it

'Vaccine

New air purifier tech could be key to improving indoor air quality

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Moonlake's readout produced a cash windfall. Risks remain

FDA rejects Alnylam's heart disease treatment over insufficient data

leisure time

Chemotherapy drug shortage eases slightly but still widespread

'Vaccine

Elisabeth Bik tackles the widespread issue of research misconduct

Are embryos people? Reproductive medicine's future depends on the answer

VC firm General Catalyst wants to buy a health system

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

knowledge

entertainment

entertainment

focus